tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

GTHX Stock Latest News

G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
Press ReleasesG1 Therapeutics Added to the Russell 2000® and 3000® Indexes
40m ago
GTHX
G1 Therapeutics price target lowered to $6 from $12 at Needham
PremiumThe Fly
G1 Therapeutics price target lowered to $6 from $12 at Needham
6d ago
GTHX
G1 Therapeutics price target lowered to $3 from $9 at H.C. Wainwright
PremiumThe Fly
G1 Therapeutics price target lowered to $3 from $9 at H.C. Wainwright
6d ago
GTHX
G1 Therapeutics Reports Setback in Phase 3 Cancer Trial
PremiumCompany Announcements
G1 Therapeutics Reports Setback in Phase 3 Cancer Trial
7d ago
8K
GTHX
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
PremiumPress Releases
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
7d ago
GTHX
G1 Therapeutics backs FY24 COSELA net revenue view $60M-$70M
PremiumThe FlyG1 Therapeutics backs FY24 COSELA net revenue view $60M-$70M
7d ago
GTHX
G1 Therapeutics provides update on Phase 3 PRESERVE 2 trial of trilaciclib
PremiumThe Fly
G1 Therapeutics provides update on Phase 3 PRESERVE 2 trial of trilaciclib
7d ago
GTHX
G1 Therapeutics participates in a conference call with JPMorgan
PremiumThe Fly
G1 Therapeutics participates in a conference call with JPMorgan
16d ago
GTHX
G1 Therapeutics announces inducement grants under Nasdaq listing rule
PremiumThe Fly
G1 Therapeutics announces inducement grants under Nasdaq listing rule
26d ago
GTHX
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26d ago
GTHX
G1 Therapeutics’ trilaciclib combiation improves breast cancer overall survival
PremiumThe Fly
G1 Therapeutics’ trilaciclib combiation improves breast cancer overall survival
1M ago
GTHX
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
PremiumPress Releases
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
1M ago
GTHX
G1 Therapeutics announces upcoming presentation on trilaciclib at ASOCO
PremiumThe FlyG1 Therapeutics announces upcoming presentation on trilaciclib at ASOCO
1M ago
GTHX
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
PremiumPress Releases
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
1M ago
GTHX
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit
PremiumPress Releases
G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit
1M ago
GTHX
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
PremiumPress Releases
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
1M ago
GTHX
G1 Therapeutics announces global licensing agreement for lerociclib
PremiumThe Fly
G1 Therapeutics announces global licensing agreement for lerociclib
1M ago
GTHX
G1 Therapeutics strength attributed to M&A speculation, says Raymond James
PremiumThe Fly
G1 Therapeutics strength attributed to M&A speculation, says Raymond James
2M ago
GTHX
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2M ago
GTHX
G1 Therapeutics reaffirms FY24 guidance
PremiumThe FlyG1 Therapeutics reaffirms FY24 guidance
2M ago
GTHX
G1 Therapeutics reports Q1 EPS (20c), consensus (21c)
PremiumThe Fly
G1 Therapeutics reports Q1 EPS (20c), consensus (21c)
2M ago
GTHX
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
PremiumPress Releases
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
2M ago
GTHX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >